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Background: The zygapophysial (facet) joint is the primary pain generator in one third of chronic low back pain
cases. Current treatment options include temporarily palliative nonsurgical approaches, facet injections,
radiofrequency denervation, and, rarely, lumbar arthrodesis. The purpose of this study was to assess the safety and
effectiveness of a minimally invasive implant intended to restore facet joint function in patients with chronic
lumbar facetogenic pain.
Methods: This prospective, multi-center feasibility study enrolled patients with confirmed lumbar facetogenic joint
pain at 1 or 2 levels who underwent at least 6 months of unsuccessful nonoperative care. Patients received a
minimally invasive implant (Glyder® Facet Restoration Device, Zyga Technology, Inc., Minnetonka, MN) intended to
restore facet joint function while preserving the native anatomy. Main outcomes included back pain severity using
a visual analogue scale, back-specific disability using the Oswestry Disability Index (ODI), and adverse events
adjudicated by an independent Clinical Events Committee.
Results: Of 40 enrolled patients, 37 patients received the facet restoration implant and 34 patients had complete
1-year follow-up data available. Over the 1-year follow-up period, back pain severity decreased 41% and ODI
decreased 34%, on average. Freedom from a device- or procedure-related serious adverse event through 1 year
was 84%. Implant migration was observed in 3 patients and implant expulsion from the facet joint occurred in 3
patients. In total, 2 (5.4%) patients underwent implant removal through 1 year post-treatment.
Conclusions: A minimally invasive facet restoration implant is a promising treatment option in select patients with
chronic lumbar zygapophysial pain who have exhausted nonsurgical treatments, with therapeutic benefit persisting
at 1 year follow-up.
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The basic anatomic unit of the spine is a three-joint
complex comprised of an intervertebral disc and paired
zygapophysial (facet) joints. The main function of the
facet joints is to limit movement in all planes of motion
with a secondary role in weight bearing. Facet joints bear
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stated.even greater loads in the presence of decreased disc height
[1]. Results of animal [2,3] and cadaveric [4-6] studies sup-
port the hypothesis that repetitive strain accumulated over
a lifetime increases the risk for facet arthropathy, similar
to other synovial joints. In humans, degenerative changes
in any component of the anatomic unit predictably lead to
concomitant degenerative changes in the other compo-
nents [7-10]. Since the risk for disc height reduction in-
creases with age, facet joint arthropathy is also relatively
common in older adults. Although the facet joints are re-
sponsible for 1 in 3 cases of chronic low back pain, second
in frequency only to degenerative disc disease [11], theLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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underappreciated due to difficulties in differential diagno-
sis and lack of consensus in optimal management of this
condition.
Current treatment options include temporarily pallia-
tive approaches such as conservative care, medical man-
agement, corticosteroid injection, and radiofrequency
denervation. Lumbar arthrodesis is typically reserved for
patients with late-stage disease who have exhausted non-
surgical treatments although no convincing evidence exists
to support this procedure for facetogenic pain [12-14].
There is an obvious therapeutic gap for patients with
chronic lumbar facetogenic joint pain who have unsuccess-
fully exhausted conservative treatments. The purpose of
this feasibility study was to assess the safety and effective-
ness of a minimally invasive implant intended to restore




All experimental procedures performed in this study were
in strict accordance with a pre-defined protocol that was
approved by all researchers and the local ethics commit-
tees (Santa Rita Independent Research Ethics Committee
(Sao Paulo, Brazil) and Ethics Committee of the Medical
Association of Saxony-Anhalt (Halle, Germany). Subjects
provided informed consent before study participation.
Study design
This prospective, multi-center, feasibility study was con-
ducted at four investigative sites in Germany and Brazil
under a common study protocol. The protocol specified
enrollment of 40 patients with chronic facet joint pain at
one or two levels. Patients were grouped based on surgi-
cal history. Group 1 had no previous surgery (other than
discectomy) at the index level or adjacent level. Group 2
had previous surgery (other than discectomy) at the
index level and/or adjacent level. Prior arthrodesis or
facetectomy at the index level was contraindicated in
both groups.
Participants
Eligible patients underwent at least 6 months of nonopera-
tive care and presented with radiographic (CT or MRI) evi-
dence of facet disease at one or two levels from L1 to S1,
verified by at least one positive (≥20 mm reduction in back
pain on a visual analogue scale, (VAS) intraarticular/peri-
articular facet injection in the last 6 months. Additional in-
clusion criteria included surgical candidates age ≥18 years,
pain severity ≥60 mm (with predominantly back symp-
toms), and Oswestry Disability Index (ODI) ≥40%. Main ex-
clusion criteria were active infection, morbid obesity,
pregnancy, grade 3 or 4 osteoarthritis [15], osteoporosis orsevere osteopenia, tumor, cyst, fracture, spondylolysis,
spondylolisthesis >3 mm, disc collapse ≥50%, or neuro-
logical deficit at the index or adjacent level.
Preoperative evaluation
Preoperative evaluation included demographics, medical
history, back and leg pain severity, ODI, orthopedic exam-
ination, and imaging. The orthopedic examination in-
cluded palpation of the index facet joint and loading of the
joint in flexion/extension and lateral bending. Imaging
evaluations included MRI or CT and 4-view x-rays within
6 months of study enrollment.
Implant
The Glyder® Facet Restoration Device (Zyga Technology,
Inc., Minnetonka, MN) is intended for treatment of pa-
tients with chronic facetogenic pain from L2 to sacrum,
confirmed by diagnostic facet injection, due to degenera-
tive facet joint disease or mechanical joint disease. The
Glyder Device consists of a pair of PEEK-OPTIMA® wa-
fers implanted in each facet joint. Each wafer has a
smooth side to restore the sliding surface and a textured
side that engages the articulating surface of the facet to pre-
vent migration. Each implant also contains a platinum/irid-
ium marker encapsulated within the body to enhance
implant visualization under radiographic evaluation. The
device is intended to relieve facet joint pain by restoring
facet joint function, preserving the native anatomy without
compromising future treatment options.Procedure
Close inspection of preoperative imaging is mandatory
to inform proper access trajectory and identify possible
structures that may interfere with implantation such as
large osteophytes, inadequate joint size such as <14 mm
height and depth, or extreme posterolateral access angles
that may result in occlusion by the iliac crest. The patient
is positioned prone on a radiolucent spine table with lor-
dosis maintained and the skin is prepped and draped.
Under oblique fluoroscopic guidance, the correct level is
identified and the posterolateral entry point is marked. A
2–3 cm skin incision is made followed by blunt dissection
to the facet joint capsule. The joint line is radiographically
identified and a small (3–5 mm) incision is made along
the joint line on the posterior aspect of the facet capsule
to open the facet joint (Figure 1a). The maximum amount
of facet joint capsule should be preserved to maintain
joint stability. Following slight distraction between
both facet joint surfaces (Figure 1b), the Glyder im-
plants are delivered with a dedicated tool through a
cannula (Figure 1c). Following implant delivery (Figure 1d),
direct and fluoroscopic visualization in two planes con-
firms correct positioning.
Figure 1 Major facet restoration procedural steps including: a) joint access, b) distraction of the facet joint, c) implant insertion, and
d) final implant position. Facet capsule has been removed from cadaver for visibility, but is preserved during implantation.
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Patients were advised to avoid prolonged sitting, extreme
bending or twisting, and lifting weights >5 kg during re-
covery. Typical recovery periods were 1 week to return to
driving, 1–3 weeks to return to a sedentary job, and
6 weeks for return to sport or physically demanding work.
Patients were followed through hospital discharge and
returned for follow-up visits at 6 weeks and 3, 6, and
12 months, which included a questionnaire, clinical exam-
ination and flexion/extension x-rays.
Endpoints
The protocol defined effectiveness outcomes included
back pain severity on a 0 to 100 mm VAS and back-
specific disability using the ODI. Back pain clinical suc-
cess was defined as a ≥20 mm decrease in back pain
severity compared to pre-treatment values [16,17]. Back
function clinical success was defined as an absolute de-
crease in ODI of ≥15 percentage points compared to
pre-treatment values [16]. Patient safety was assessed by
recording all adverse events, regardless of severity or re-
lationship to the device or procedure. An independent
Clinical Events Committee (CEC) reviewed and adjudi-
cated all events classified by the investigators as serious
(SAE), device-related, and/or procedure-related.
Statistical methods
All data were recorded on standardized case report forms
and independently monitored for accuracy. Continuousvariables were reported as mean ± SD or median (min-
max), depending on normality assumptions. Categorical
variables were presented as n (%). Longitudinal outcomes
were analyzed with repeated measures analysis of variance;
values were reported as mean ±95% CI. Missing values
accounted for <5% of VAS and ODI data and were conser-
vatively imputed using the last observation carried forward
(LOCF) technique [18]. Statistical analyses were performed
using SPSS version 22 (IBM, Inc., Armonk, NY, USA).
Results
A total of 40 patients (Group 1, n = 24; Group 2, n = 16)
were enrolled at 4 investigative sites in Germany and
Brazil between November 2009 and January 2013. One pa-
tient was discontinued from the study due to a negative
diagnostic facet injection prior to the procedure. Two pa-
tients were discontinued when the procedure was aborted
intraoperatively due to large osteophytes interfering with
joint access. Ultimately, 37 patients were implanted with
the facet restoration device. Two enrolled patients had
grade 3 or 4 osteoarthritis at the index level (Table 1). Im-
plants were routinely placed bilaterally at one (n = 31) or
two (n = 4) levels. Two patients received a single implant
at one level due to an inaccessible or non-implantable
joint line at the contralateral facet. Both patients remained
in the study and completed 1-year follow-up, one with no
change in symptoms and the other with complete symp-
tom relief. The minimally invasive procedure was associ-
ated with minimal blood loss and patients were typically
Table 1 Baseline patient characteristics
Variable Value
N = 37
Male gender, n (%) 19 (51)
Age, yr 52 ± 13
Body mass index, kg/m2 27 ± 5
Oswestry Disability Index,% 54 ± 13
Back pain severity, 0–100 scale 77 ± 13
Leg pain severity, 0–100 scale 45 ± 38
Facetogenic pain duration, yr 2 (0–36)





Previous nonsurgical treatments, n (%) 37 (100)
-Injection, n 37
-Medication, n 32
-Physical therapy, n 28
-Exercise, n 23
-Chiropractic, n 9
Previous back surgeries, n (%) 25 (68)
-Fusion, n 9
-Discectomy, n 7
-Total disc replacement, n 7
-Facet procedure, n 6
-Disc nucleoplasty, n 2
-Decompression, n 1
Previous back surgery location, n (%)
-Any level (L1 to S1) 25 (68)
-Index level 17 (46)
-Adjacent level 18 (49)
Continuous data expressed as mean ± sd or median (min-max).








Levels with bilateral implants, n (%) 39 (95)
Procedure duration, min 80 (30–210)
Procedural blood loss, ml 50 (0–150)
Hospital stay, days 2 (0–6)
Continuous data expressed as median (min-max).
Figure 2 Change in visual analogue scale for back pain severity
through 1 year.
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1-year follow-up data were available for 34 (92%) of 37 pa-
tients who received an implant. Reasons for missing 1-
year follow-up visits included 2 patients who were lost to
follow-up and one patient who withdrew from the study
following device explant at 9 months.
Back pain severity declined 35% on average through
6 week follow-up and remained stable through 1 year.
Compared to pre-treatment values, back pain severity
scores at 1 year were significantly lower (77 ± 13 to 45 ±
29, p < 0.001) (Figure 2). At 1 year, 59% of patients re-
ported at least a 20 mm reduction in back pain com-
pared to pre-treatment. Back function improved by
34% on average during this period (54 ± 13 to 36 ± 21,p < 0.001) (Figure 3). At 1 year, 50% of patients re-
ported an absolute ODI decrease ≥15 percentage
points. No significant differences were noted between
Groups 1 and 2 for any outcome.
Overall, 10 SAEs were reported in 8 (22%) patients. The
CEC classified the events as related to the device (3), pro-
cedure (2), both (2), or neither (3) (Table 3). Freedom
from a device- or procedure-related SAE through 1 year
was 84% (Figure 4). Surgical wound infection occurred in
two patients, one of which resulted in removal of the de-
vice in accordance with hospital policy. Implant migration
defined as movement of the device in the joint was ob-
served in three patients, two of which were defined as ser-
ious. One migrated device was removed due to the
previously described wound infection. Implant expulsion
demonstrated by evidence that the device exited the facet
joint occurred in three patients, one of which required re-
moval. In total, 2 (5.4%) patients underwent implant re-
moval through 1 year post-treatment.
Figure 3 Change in Oswestry Disability Index through 1 year.
Figure 4 Kaplan-Meier estimate of freedom from device- or
procedure-related serious adverse event through 1 year.
SAE: serious adverse event.
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The results of this prospective feasibility study suggest
that facet restoration may be a viable treatment option
in select patients with chronic lumbar zygapophysial pain,
with therapeutic benefit persisting at 1 year follow-up. In
comparison, the duration of therapeutic effect is typically
3 to 6 months with intraarticular corticosteroid injection
[19-21] and 3 to 12 months with radiofrequency denerv-
ation [22-25]. Facet restoration implants may help to fill
the therapeutic void in patients who have exhausted non-
surgical treatments.
This is only the second published study of minimally
invasive lumbar facet restoration. A recent study by Van
de Kelft [26] reported outcomes in 8 patients treated
with the FENIX™ facet resurfacing implant for lumbar
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h Implant migration 1 Device Nopromising with a 72% reduction in back pain severity and
66% improvement in ODI at 1 year. One (12.5%) implant
migration was observed at 2 years follow-up, which was
treated with implant removal and posterior lumbar inter-
body fusion. Compared to the FENIX implant, a unique
aspect of the Glyder Device is that no screws are required
to maintain fixation. Instead, implant position is maintained
by the textured surface gripping the facet articulating sur-
face. This allows for a simple implantation procedure that
preserves the native anatomy and, if needed, a straightfor-
ward explant. Additional studies are needed to clarify the
comparative clinical utility of this implant design over the
long term.
Five patients reported a clicking sensation immediately
following implantation. In all cases, there were no adverse
outcomes and the sensation eventually resolved without
intervention. Presence of large osteophytes should be an
absolute contraindication, as evidenced by two cases of
unsuccessful implantation attempt in such patients. Al-
though avoidance of implant migration is an intuitive con-
cept, the clinical significance of this event is yet to be
determined. Two patients with implant migration/expul-
sion underwent implant removal though it is unlikely that
implant migration/expulsion in and of itself would elicit
symptoms. Posterior implant expulsion should be benign
since the device will simply imbed in the spinal muscula-
ture. Anterior migration is unlikely due to presence of the
ligamentum flavum on the anterior portion of the facet
joint. Nonetheless, implant migration is an untoward risk
that can be mitigated with proper patient selection (e.g.
adequate joint height and depth, proper facet osteoarth-
ritis grade) and meticulous attention to device placement.
Limitations of this study included lack of a control
group and a somewhat heterogeneous patient popula-
tion. Arguably, use of ≥20 mm improvement in VAS
back pain severity as the criterion for a positive diagnos-
tic injection in this study may be viewed as conservative
Meisel et al. Annals of Surgical Innovation and Research 2014, 8:7 Page 6 of 6
http://www.asir-journal.com/content/8/1/7with potential for false positives. Lessons learned from
this feasibility study have led to modifications in implant
design, implantation procedure, and patient selection.
Conclusions
A minimally invasive facet restoration implant is a promis-
ing treatment option in select patients with chronic lum-
bar zygapophysial pain who have exhausted nonsurgical
treatments, with therapeutic benefit persisting at 1 year
follow-up.
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